Research brokerage firms on Wall Street are offering a consensus “Buy” rating on shares of MacroGenics, Inc. (NASDAQ:MGNX). Using the following ratings scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell and 5.0 Strong Sell, analysts have an average recommendation of 1.80 on the shares. Based on a recent trade, the shares are hovering around $20.76 which, according to analysts, yield significant upside potential to the $33.75 consensus target price.
Even extremely solid stocks can sporadically face setbacks. There is no shortage of news regarding publically traded companies, and investors Often times have the tricky job of deciding what information is worth taking a closer look at. Making trading decisions based on one piece of data may not be the optimal period of action. When there is negative information about a firm, investors may be quick to sell without surveying deeper into the numbers. On the flip side, investors may be super quick to buy on good news without fully researching the stock.
Wall Street firms hire hundreds of analysts who provide recommendations on stocks. Typically, these analysts look at a firm’s fundamentals, building financial models from this information in order to project future trends, specifically future earnings.
These projections are then used as a basis for providing “buy” or “sell” recommendations. Many investors consider these recommendations very seriously, and Often times times whenever an expert adjustments their outlook on a stock, the price change almost immediately.
Analyst recommendations should be approached with caution for many reasons. Many times a conflict of interest arises due to the relationship between firm that they work for and the firm whose stock they are paid to track. Often, analysts are responsible for creating reports on companies that are presently or could potentially be a client of their employer. Analysts don’t want to offend any companies that could possibly be a potential client down the road, so they are inclined to put a positive spin on the stock.
Earnings estimates can also be manipulated, as the analysts are inclined to minimize them so that it increases the chances that a stock will “beat” the artificially lowered estimate in order to get novice investors to buy.
RSI
MacroGenics, Inc. (NASDAQ:MGNX)’s shares may have a significant upside to the consensus target of 33.75, but how has it been performing relative to the market? The stock’s price is 20.76 and their relative strength index (RSI) stands at 42.24. RSI is a technical oscillator that reveals price strength by comparing upward and downward movements. It reveals oversold and overbought price levels for a stock.
MacroGenics, Inc. (NASDAQ:MGNX) shares are moving -3.08% trading at $20.76 today,
Investors might be surveying high and low for quality stocks that have fallen out of favor with the investing community. There are plenty of stocks that get continuous coverage from the big media outlets, but there are many others that may be hiding behind the scenes. Conducting thorough stock due diligence can aid the investor isolate certain stocks that might be ready for a near-term bounce. With the equity market still trading near record levels, investors will be surveying for any opportunity to pounce on shares that might have been left behind for whatever reason.
